Autism Spectrum Illness (ASD) is a neurological disorder that is linked to and frequently overlaps with other ailments such as epilepsy, recurrent infections, sleep difficulties, anxiety, depression, and gastrointestinal issues. ASD can only be identified via developmental and thorough testing. It can be discovered between the ages of eighteen months and two years. Aripiprazole, Risperidone, and Melatonin are FDA-approved medicines that help with the treatment of autism spectrum disorder. Bumetanide and Balovaptan are two medicines undergoing clinical trials and research to determine their safety and efficacy in the treatment of ASD.
The worldwide autism spectrum disorder therapeutics (ASD) therapeutics market was valued at US$ 2,169.3 million in 2018 and is anticipated to grow at a 6.8 percent CAGR from 2018 to 2026.
The launch of innovative medicines by key companies and the rising number of pipeline medications are likely to be the primary driving factors for the global autism spectrum disorder therapeutics market development during the forecast period. For example, in February 2014, the firm received six additional patents in Europe, Australia, and Central America for their enzyme delivery system, which may be used for a variety of enzyme products, including CM-AT, Curemark's patented ASD medication. In addition, in September 2017, Caremark launched a second Phase III clinical research, the Blüm Study, to assess the safety and effectiveness of CM-AT in children aged 3 to 8 with ASD.